Literature DB >> 15522214

Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter.

David Dingli1, Elizabeth R Bergert, Zeljko Bajzer, Michael K O'connor, Stephen J Russell, John C Morris.   

Abstract

The thyroidal sodium iodide symporter (NIS) in combination with various radioactive isotopes has shown promise as a therapeutic gene in various tumor models. Therapy depends on adequate retention of the isotope in the tumor. We hypothesized that in the absence of iodide organification, isotope trapping is a dynamic process either due to slow efflux or re-uptake of the isotope by cells expressing NIS. Iodide efflux is slower in ARH-77 and K-562 cells expressing NIS compared to a thyroid cell line. Isotope retention half times varied linearly with the number of cells expressing NIS. With sufficient NIS expression, iodide efflux is a zero-order process. Efflux kinetics in the presence or absence of perchlorate also supports the hypothesis that iodide re-uptake occurs and contributes to the retention of the isotope in tumor cells. Iodide organification was insignificant. In vivo studies in tumors composed of mixed cell populations confirmed these observations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15522214     DOI: 10.1016/j.bbrc.2004.09.219

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  18 in total

Review 1.  Attenuated oncolytic measles virus strains as cancer therapeutics.

Authors:  P Msaouel; I D Iankov; A Dispenzieri; E Galanis
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

Review 2.  The Na+/I- symporter (NIS): mechanism and medical impact.

Authors:  Carla Portulano; Monika Paroder-Belenitsky; Nancy Carrasco
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

Review 3.  Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Angela Dispenzieri; Kah Whye Peng; Mark J Federspiel; Stephen J Russell; Evanthia Galanis
Journal:  Curr Cancer Drug Targets       Date:  2018       Impact factor: 3.428

4.  Efficacy of 99mTc pertechnetate and 131I radioisotope therapy in sodium/iodide symporter (NIS)-expressing neuroendocrine tumors in vivo.

Authors:  Meike L Schipper; Christoph G U Riese; Stephan Seitz; Alexander Weber; Martin Béhé; Tino Schurrat; Nils Schramm; Boris Keil; Heiko Alfke; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-08       Impact factor: 9.236

5.  Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome.

Authors:  Linh Pham; Takafumi Nakamura; A Gabriela Rosales; Stephanie K Carlson; Kent R Bailey; Kah-Whye Peng; Stephen J Russell
Journal:  J Gene Med       Date:  2009-03       Impact factor: 4.565

6.  Effective treatment of pancreatic neuroendocrine tumours transfected with the sodium iodide symporter gene by 186Re-perrhenate in mice.

Authors:  Christoph G U Riese; Stephan Seitz; Meike L Schipper; Thomas M Behr
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-16       Impact factor: 9.236

Review 7.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

Review 8.  Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview.

Authors:  Pavlos Msaouel; Angela Dispenzieri; Evanthia Galanis
Journal:  Curr Opin Mol Ther       Date:  2009-02

9.  Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.

Authors:  Emily K Mader; Greg Butler; Sean C Dowdy; Andrea Mariani; Keith L Knutson; Mark J Federspiel; Stephen J Russell; Evanthia Galanis; Allan B Dietz; Kah-Whye Peng
Journal:  J Transl Med       Date:  2013-01-24       Impact factor: 5.531

10.  Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine.

Authors:  Brian Hutzen; Christopher R Pierson; Stephen J Russell; Evanthia Galanis; Corey Raffel; Adam W Studebaker
Journal:  BMC Cancer       Date:  2012-11-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.